
AIM Stock Forecast & Price Target
AIM Analyst Ratings
Bulls say
AIM ImmunoTech Inc. has garnered a positive outlook due to the encouraging results from multiple clinical studies involving its flagship product, Ampligen, particularly in treating various cancers and post-COVID conditions. Recent advancements, including a Phase 2a study demonstrating the efficacy of Ampligen in colorectal cancer and a Phase 2 study for post-COVID patients, provide strong catalysts for potential stock appreciation. The company's focus on pancreatic cancer and its ability to address unmet medical needs further enhance its growth prospects, presenting significant upside opportunities despite inherent risks associated with the biotech sector.
Bears say
AIM ImmunoTech Inc. reported a net loss of $3.3 million for the latest period, translating to an earnings per share (EPS) of $(1.57), which significantly exceeded both internal and consensus estimates. Additionally, the prior period reflected an even higher net loss of $4.2 million with an EPS of $(1.39), also surpassing expected figures. The company faces numerous risks impacting its share price, including liquidity issues, challenges in clinical trial success, regulatory hurdles, commercialization difficulties, and competitive pressures, which collectively suggest a concerning outlook for its financial stability and future growth potential.
This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.
AIM Analyst Forecast & Price Prediction
Start investing in AIM
Order type
Buy in
Order amount
Est. shares
0 shares